1
Van der Linden, N., Van Olst, S., Nekeman, S., Uyl-de Groot, C. A.
Veröffentlicht in: Van der Linden , N , Van Olst , S , Nekeman , S & Uyl-de Groot , C A 2021 , ' The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands ' , Diabetic Medicine , vol. 38 , no. 4 , e14371 . https://doi.org/10.1111/dme.14371;
2021
Veröffentlicht in: Van der Linden , N , Van Olst , S , Nekeman , S & Uyl-de Groot , C A 2021 , ' The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands ' , Diabetic Medicine , vol. 38 , no. 4 , e14371 . https://doi.org/10.1111/dme.14371;
2021